Abstract
Introduction: S-1 is an oral combination of tegafur (a prodrug of 5-fluorouracil (5-FU)) and two modulators of 5-FU metabolism, gimeracil and oteracil. This combination was optimized to reduce the toxicity of 5-FU due to toxic metabolites. S-1 in combination with cisplatin is approved for use in AGC in Europe since 2011. We report here post-approval safety data for 11 AGC patients treated with S-1 regimens in daily practice including combination with oxaliplatin (SOX) and trastuzumab. Data were collected in the observational Study of Compliance Observed with Oral fluoro Pyrimidine Teysuno (SCOOP).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.